164 related articles for article (PubMed ID: 31598605)
1. Certolizumab Pegol Treatment in Three Patients With Takayasu Arteritis.
Ataş N; Varan Ö; Babaoğlu H; Satiş H; Bilici Salman R; Tufan A
Arch Rheumatol; 2019 Sep; 34(3):357-362. PubMed ID: 31598605
[TBL] [Abstract][Full Text] [Related]
2. Certolizumab pegol in the treatment of Takayasu arteritis.
Novikov PI; Smitienko IO; Sokolova MV; Alibaz-Oner F; Kaymaz-Tahra S; Direskeneli H; Moiseev SV
Rheumatology (Oxford); 2018 Dec; 57(12):2101-2105. PubMed ID: 30010945
[TBL] [Abstract][Full Text] [Related]
3. Summary of certolizumab pegol in psoriasis including structural features, pharmacokinetics and treatment.
Tokuyama M; Mabuchi T
Immunotherapy; 2024 Mar; 16(5):273-285. PubMed ID: 38319071
[TBL] [Abstract][Full Text] [Related]
4. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer.
Porter C; Armstrong-Fisher S; Kopotsha T; Smith B; Baker T; Kevorkian L; Nesbitt A
J Reprod Immunol; 2016 Aug; 116():7-12. PubMed ID: 27123565
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
Nesbitt A; Fossati G; Bergin M; Stephens P; Stephens S; Foulkes R; Brown D; Robinson M; Bourne T
Inflamm Bowel Dis; 2007 Nov; 13(11):1323-32. PubMed ID: 17636564
[TBL] [Abstract][Full Text] [Related]
7. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis.
Launois R; Avouac B; Berenbaum F; Blin O; Bru I; Fautrel B; Joubert JM; Sibilia J; Combe B
J Rheumatol; 2011 May; 38(5):835-45. PubMed ID: 21239748
[TBL] [Abstract][Full Text] [Related]
8. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action.
Bourne T; Fossati G; Nesbitt A
BioDrugs; 2008; 22(5):331-7. PubMed ID: 18778114
[TBL] [Abstract][Full Text] [Related]
9. Patient adherence and efficacy of certolizumab pegol in the management of Crohn's disease.
Blonski W; Buchner AM; Lichtenstein GR
Clin Med Insights Gastroenterol; 2012; 5():11-21. PubMed ID: 24833930
[TBL] [Abstract][Full Text] [Related]
10. Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy.
Marin J; Acosta Felquer ML; Soriano ER
Open Access Rheumatol; 2018; 10():33-41. PubMed ID: 29765257
[TBL] [Abstract][Full Text] [Related]
11. One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.
Harrold LR; Litman HJ; Saunders KC; Dandreo KJ; Gershenson B; Greenberg JD; Low R; Stark J; Suruki R; Jaganathan S; Kremer JM; Yassine M
Arthritis Res Ther; 2018 Jan; 20(1):2. PubMed ID: 29329557
[TBL] [Abstract][Full Text] [Related]
12. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
[TBL] [Abstract][Full Text] [Related]
13. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease.
Hanauer SB; Panes J; Colombel JF; Bloomfield R; Schreiber S; Sandborn WJ
Aliment Pharmacol Ther; 2010 Aug; 32(3):384-93. PubMed ID: 20491747
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.
Schoepfer AM; Vavricka SR; Binek J; Felley C; Geyer M; Manz M; Rogler G; de Saussure P; Sauter B; Seibold F; Straumann A; Michetti P;
Inflamm Bowel Dis; 2010 Jun; 16(6):933-8. PubMed ID: 20014021
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey.
Vavricka SR; Spasojevic M; Rogler G; Schoepfer AM; Seibold F; Borovicka J; Frei P; Zeitz J; Greuter T; Manser C; Scharl M; Misselwitz B; Straumann A; Michetti P; Biedermann L;
Dig Dis; 2017; 35(5):423-432. PubMed ID: 28595194
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease.
Tun GS; Lobo AJ
Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):317-27. PubMed ID: 25586216
[TBL] [Abstract][Full Text] [Related]
17. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
18. Certolizumab pegol for the treatment of psoriatic arthritis.
Hansen RB; Kavanaugh A
Expert Rev Clin Immunol; 2015 Mar; 11(3):307-18. PubMed ID: 25651776
[TBL] [Abstract][Full Text] [Related]
19. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis.
Palframan R; Airey M; Moore A; Vugler A; Nesbitt A
J Immunol Methods; 2009 Aug; 348(1-2):36-41. PubMed ID: 19567252
[TBL] [Abstract][Full Text] [Related]
20. Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis.
Domańska B; VanLunen B; Peterson L; Mountian I; Schiff M
Expert Opin Drug Deliv; 2017 Jan; 14(1):15-22. PubMed ID: 27801596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]